Teladoc Health, Inc. TDOC recently introduced new enhancements to its proprietary care delivery platform, Prism. The platform has enabled the company to achieve a competitive edge due to its extensive reach and capability to provide a wide range of high-quality virtual healthcare services. 

As a result of the new advancements, the platform now features improved data integration and administrative tools that automatically identify and highlight recommended screenings and diagnostic assessments. This ensures that Teladoc Health’s care teams have access to key insights, enabling them to address health gaps more effectively during patient interactions. Additionally, clinicians and health coaches can now seamlessly access member eligibility information and refer patients to Teladoc Health’s Connected Care Partners. 

Another significant advancement is the expanded closed-loop referral functionality, which now allows Teladoc Health care teams to connect patients with in-network community care providers. Previously, this feature was exclusive to the company’s Primary360 program. To further enhance clinical efficiency, the platform has also introduced AI-powered clinical transcription tools that streamline documentation. These tools capture and structure patient notes in real time, ensuring high-quality record-keeping while reducing the administrative burden for healthcare providers.

The recently introduced enhancements are designed to improve care coordination with digital health partners and community healthcare providers. The upgraded platform facilitates more efficient referrals to Teladoc Health’s digital and in-person care networks while leveraging data-driven insights to enhance virtual care visits. By enabling clinicians to address care gaps more effectively, these updates support improved health outcomes for individuals covered by employer-sponsored and health plan services.

Benefits of the Recent Move to Teladoc Health

The lucrativeness of the Prism platform is expected to get a boost as a result of the recent capability additions. This, in turn, may attract more members to TDOC and subsequently boost revenues of its Integrated Care segment in the days ahead. Revenues in the segment improved 4% year over year in 2024.  

Currently, more than 93 million Americans have access to at least one Teladoc Health offering through their employer or health plan. The efficiency of its proprietary care delivery platform enables 90% of Teladoc Health’s virtual urgent care visits to be completed within 30 minutes of a member’s outreach.

TDOC’s Share Price Performance & Zacks Rank

Shares of Teladoc Health have gained 57.6% year to date compared with the industry’s 2.2% growth. TDOC currently carries a Zacks Rank #3 (Hold).

Image Source: Zacks Investment Research

Stocks to Consider

Some better-ranked stocks in the Medical space are Option Care Health, Inc. OPCH, The Ensign Group, Inc. ENSG and BioMarin Pharmaceutical Inc. BMRN. While Option Care currently sports a Zacks Rank #1 (Strong Buy), Ensign Group and BioMarin Pharmaceutical carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Option Care’s earnings surpassed the Zacks Consensus Estimate in each of the last four quarters, the average surprise being 15.91%. The consensus estimate for OPCH’s 2025 earnings indicates a rise of 38.2%, while the consensus mark for revenues implies an improvement of 8.3% from the corresponding year-ago figures. 

The consensus estimate for OPCH’s 2025 earnings has moved 34.9% north in the past seven days. Shares of Option Care have gained 49% year to date. 

Ensign Group’s earnings outpaced the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 1.48%. The consensus estimate for ENSG’s 2025 earnings indicates a rise of 12.7% from the year-ago figure. The consensus mark for revenues indicates growth of 14.3% from the year-ago figure. 

The consensus estimate for ENSG’s 2025 earnings has moved 2% north in the past 30 days. Shares of Ensign Group have lost 2.6% year to date. 

BioMarin Pharmaceutical’s earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 32.36%. The consensus estimate for BMRN’s 2025 earnings indicates a rise of 20.5%, while the consensus mark for revenues implies an improvement of 10% from the corresponding year-ago figures. 

The Zacks Consensus Estimate for BMRN’s 2025 earnings has moved 1.2% north in the past seven days. Shares of BioMarin Pharmaceutical have rallied 7.6% year to date.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report

The Ensign Group, Inc. (ENSG) : Free Stock Analysis Report

Teladoc Health, Inc. (TDOC) : Free Stock Analysis Report

Option Care Health, Inc. (OPCH) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research